CARLIN S LONG, MD
Osteopathic Medicine at Bannock St, Denver, CO
License number
Colorado 37070
Category
Osteopathic Medicine
Type
Cardiovascular Disease
Address
Address
777 Bannock St, Denver, CO 80204
Phone
(303) 436-6000
Personal information
See more information about CARLIN S LONG at radaris.comName
Address
Phone
1745 Locust St, Denver, CO 80220
Denver, CO
1745 Locust St, Denver, CO 80220
Organization information
See more information about CARLIN S LONG at bizstanding.comCarlin S Long MD
700 Delaware St #3, Denver, CO 80204
Categories:
Cardiology Physicians & Surgeons
Phone:
(303) 602-6170 (Phone)
Professional information
See more information about CARLIN S LONG at trustoria.com
Dr. Carlin Long, Denver CO - MD (Doctor of Medicine)
Dr. Carlin Long, Denver CO - MD (Doctor of Medicine)
Specialties:
Cardiology
Address:
777 Bannock St, Denver 80204
(303) 436-5499 (Phone)
(303) 436-5499 (Phone)
Procedures:
Cardiac Catheterization (incl. Coronary Angiography), Cardiac Imaging, Cardiac Myocardial Perfusion Imaging, Cardioverter-Defibrillator or Pacemaker Insertion, Removal or Repair, Chest CT (incl. Heart and Lungs), Coronary Angioplasty, Atherectomy and Stent
Conditions:
Aneurysm and Dissection of Heart, Angina and Acute Coronary Syndrome, Aortic Aneurysm, Aortic Valve Disease, Arrhythmias (incl. Atrial Fibrillation), Autonomic Disorders, Cardiomegaly, Cardiomyopathy, Congenital Heart Disease, Congestive Heart Failure, Coronary Artery Disease (CAD), Endocarditis, Heart Attack (Acute Myocardial Infarction), Heart Tumors, Benign, Hyperlipidemia, Hypertension, Hypotension, Mitral Valve Disease, Pericardial Disease, Pulmonary Hypertension, Pulmonary Valve Disease, Syncope, Tricuspid Valve Disease
Certifications:
Cardiovascular Disease, 1989, Internal Medicine, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
777 Bannock St, Denver 80204
Denver Health Medical Center
777 Bannock St, Denver 80204
Denver Health Medical Center
777 Bannock St, Denver 80204
Education:
Medical School
University Of Texas Southwestern Medical Center At Dallas Southwestern Medical School
Graduated: 1982
University Of California (San Francisco) Program
Baylor University
University Of Texas Southwestern Medical Center At Dallas Southwestern Medical School
Graduated: 1982
University Of California (San Francisco) Program
Baylor University
Chief Of Cardiology At Denver Health Medical Ctr
Chief Of Cardiology At Denver Health Medical Ctr
Position:
Chief of Cardiology at Denver Health Medical Ctr
Location:
Greater Denver Area
Industry:
Hospital & Health Care
Work:
Denver Health Medical Ctr
since Aug 1998
-
Chief of Cardiology
Education:
UT Southwestern
Doctor of Medicine (MD)
Doctor of Medicine (MD)
Carlin Shaw Long, Denver CO
Carlin Shaw Long, Denver CO
Specialties:
Internist
Address:
777 Bannock St, Denver, CO 80204
Education:
University of Texas, Southwestern Medical School (Dallas) - Doctor of Medicine
UCSF Medical Center - Residency - Internal Medicine
UCSF Medical Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Cardiovascular Disease (Internal Medicine)
Industrial Automation Consultant And Contractor
Industrial Automation Consultant And Contractor
Location:
Greater Denver Area
Industry:
Industrial Automation
Inhibition Of Histone Deacetylase As A Treatment For Cardiac Hypertrophy
Inhibition Of Histone Deacetylase As A Treatment For Cardiac Hypertrophy
US Patent:
2006006, Mar 30, 2006
Filed:
Aug 30, 2005
Appl. No.:
11/215844
Inventors:
Carlin Long - Denver CO, US
Eric Olson - Dallas TX, US
Michael Bristow - Cherry Hills Village CO, US
Timothy McKinsey - Broomfield CO, US
Eric Olson - Dallas TX, US
Michael Bristow - Cherry Hills Village CO, US
Timothy McKinsey - Broomfield CO, US
International Classification:
A61K 38/12, A61K 31/401, A61K 31/19
US Classification:
514009000, 514575000, 514423000
Abstract:
The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
Inhibition Of Histone Deacetylase As A Treatment For Cardiac Hypertrophy
Inhibition Of Histone Deacetylase As A Treatment For Cardiac Hypertrophy
US Patent:
2006002, Feb 2, 2006
Filed:
Jul 26, 2005
Appl. No.:
11/190074
Inventors:
Carlin Long - Denver CO, US
Eric Olson - Dallas TX, US
Michael Bristow - Cherry Hills Village CO, US
Timothy McKinsey - Broomfield CO, US
Eric Olson - Dallas TX, US
Michael Bristow - Cherry Hills Village CO, US
Timothy McKinsey - Broomfield CO, US
International Classification:
A61K 38/12, A61K 31/19
US Classification:
514010000, 514575000
Abstract:
The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
Inhibition Of Histone Deacetylase As A Treatment For Cardiac Hypertrophy
Inhibition Of Histone Deacetylase As A Treatment For Cardiac Hypertrophy
US Patent:
2003014, Jul 31, 2003
Filed:
Sep 26, 2002
Appl. No.:
10/256221
Inventors:
Carlin Long - Denver CO, US
Eric Olson - Dallas TX, US
Michael Bristow - Cherry Hills Village CO, US
Timothy McKinsey - Broomfield CO, US
Eric Olson - Dallas TX, US
Michael Bristow - Cherry Hills Village CO, US
Timothy McKinsey - Broomfield CO, US
International Classification:
C12Q001/68, C12Q001/34, C12Q001/37, A61K031/19, A61K031/4025
US Classification:
514/422000, 514/575000, 514/718000, 435/006000, 435/018000, 435/023000
Abstract:
The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.
Inhibition Of Histone Deacetylase As A Treatment For Cardiac Hypertrophy
Inhibition Of Histone Deacetylase As A Treatment For Cardiac Hypertrophy
US Patent:
6946441, Sep 20, 2005
Filed:
Mar 16, 2004
Appl. No.:
10/801985
Inventors:
Carlin Long - Denver CO, US
Eric N. Olson - Dallas TX, US
Michael Bristow - Cherry Hills Village CO, US
Timothy A. McKinsey - Broomfield CO, US
Eric N. Olson - Dallas TX, US
Michael Bristow - Cherry Hills Village CO, US
Timothy A. McKinsey - Broomfield CO, US
Assignee:
Regents of the University of Colorado, A Body Corporation - Boulder CO
The Board of Regents, The University of Texas System - Austin TX
The Board of Regents, The University of Texas System - Austin TX
International Classification:
A61K038/00, A61K031/47, A61K031/44, A61K031/335, A61K031/165
US Classification:
514 10, 514307, 514357, 514475, 514618, 514654
Abstract:
The present invention provides for methods of treating and preventing cardiac hypertrophy. Class II HDACs, which are known to participate in regulation of chromatin structure and gene expression, have been shown to have beneficial effects on cardiac hypertrophy. Surprisingly, the present invention demonstrates that HDAC inhibitors inhibit cardiac hypertrophy by inhibiting fetal cardiac gene expression and interfering with sarcomeric organization.